NasdaqGS - Delayed Quote USD
Kiniksa Pharmaceuticals International, plc (KNSA)
At close: October 21 at 4:00 PM EDT
After hours: October 21 at 6:02 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 0.02 | 0.07 | -0.22 | 0.62 |
| Low Estimate | -0.06 | -0.03 | -0.39 | 0.29 |
| High Estimate | 0.18 | 0.18 | 0.04 | 0.94 |
| Year Ago EPS | -0.2 | 0.35 | 0.2 | -0.22 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | 110.3M | 122.37M | 421.17M | 573.7M |
| Low Estimate | 101.47M | 117M | 413.03M | 554M |
| High Estimate | 119M | 131M | 439M | 613.11M |
| Year Ago Sales | 67.05M | 83.39M | 270.26M | 421.17M |
| Sales Growth (year/est) | 64.50% | 46.70% | 55.80% | 36.20% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.17 | -0.14 | -0.16 | -0.07 |
| EPS Actual | -0.2 | 0.35 | -0.25 | -0.06 |
| Difference | -0.03 | 0.49 | -0.09 | 0.01 |
| Surprise % | -17.60% | 350.00% | -56.20% | 14.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.02 | 0.07 | -0.22 | 0.62 |
| 7 Days Ago | 0.02 | 0.07 | -0.22 | 0.62 |
| 30 Days Ago | 0.02 | 0.07 | -0.22 | 0.62 |
| 60 Days Ago | 0.03 | 0.08 | -0.2 | 0.61 |
| 90 Days Ago | 0.04 | 0.09 | -0.06 | 0.69 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | KNSA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 110.00% | -- | -- | 3.60% |
| Next Qtr. | -80.00% | -- | -- | 7.90% |
| Current Year | -210.00% | -- | -- | 2.50% |
| Next Year | 381.80% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -104.60% | -- | -- | 11.87% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | Wedbush: Outperform to Outperform | 7/23/2024 |
| Initiated | Wells Fargo: Overweight | 5/3/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 5/1/2024 |
| Maintains | Evercore ISI Group: Outperform to Outperform | 4/24/2024 |
| Maintains | Wedbush: Outperform to Outperform | 1/2/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 7/26/2023 |
Related Tickers
PBH Prestige Consumer Healthcare Inc.
71.30
-1.72%
HCM HUTCHMED (China) Limited
20.85
-0.24%
KMDA Kamada Ltd.
5.40
-0.28%
NBIX Neurocrine Biosciences, Inc.
116.57
-1.22%
EOLS Evolus, Inc.
16.24
-2.29%
AMPH Amphastar Pharmaceuticals, Inc.
50.82
-0.04%
PCRX Pacira BioSciences, Inc.
17.33
-0.91%
ITCI Intra-Cellular Therapies, Inc.
76.91
-1.83%
PAHC Phibro Animal Health Corporation
23.65
-1.74%
CRDL Cardiol Therapeutics Inc.
1.9100
-0.52%